PSOGI World News - April 2025 Newsletter
- Abdominal Cancers Alliance
- Apr 21
- 2 min read
A quarterly newsletter with the latest news, views and announcements from Peritoneal Surface Oncology Group International (PSOGI)
Led by pioneering surgical oncologist Dr. Paul Sugarbaker, PSOGI is a collaboration of experts from around the world on the treatment of peritoneal cancer and is dedicated to improving treatment and survival of patients with peritoneal metastases. While PSOGI World News is a quarterly publication primarily intended for healthcare professionals, this issue offers valuable insights for patients and caregivers navigating these complex cancers.
We are proud to share their quarterly newsletter.
The Spring 2025 edition of the Peritoneal Surface Oncology Group International (PSOGI) newsletter highlights several advancements in the treatment of peritoneal cancers, including developments related to Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Here's a brief summary:
1. Small Bowel Transplantation for Pseudomyxoma Peritonei (PMP): Researchers are exploring small bowel transplantation as a treatment for PMP, a rare cancer characterized by mucinous tumors in the abdomen. This approach may offer new hope for patients with extensive disease.
2. Contributions from the Istituto Tumori in Milan: The Istituto Tumori in Milan has been recognized for its significant contributions to peritoneal surface oncology, including advancements in cytoreductive surgery and HIPEC techniques.
3. Upcoming Events: The newsletter lists upcoming events such as the 9th INDEPSO-ISPSM Annual Update in Peritoneal Malignancies, providing opportunities for professionals to discuss the latest research and treatments.
4. Alternatives to Traditional HIPEC: Innovations like triple and quadruple HIPEC procedures are being explored to enhance treatment effectiveness for peritoneal cancers.
5. Nordic Research on Cytoreductive Surgery and HIPEC: Updates on Nordic research efforts highlight ongoing studies aimed at improving outcomes for patients undergoing cytoreductive surgery and HIPEC.
Overall the Spring 2025 PSOGI newsletter demonstrates that there’s growing momentum and innovation in the treatment of peritoneal cancers, especially using HIPEC (Hyperthermic Intraperitoneal Chemotherapy) and cytoreductive surgery. These developments reflect a global effort to improve treatments for peritoneal cancer patients, offering new strategies and hope for better outcomes.
Read the full April 2025 issue of PSOGI World News here:
If you have questions about your diagnosis and/or treatment options, speak with your doctor to determine the best plan for you.
